In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Post Abbott Consent Decree; A Changed World for Immunoassay Vendors

Executive Summary

Abbott's prolonged problems with the FDA in the immunoassaay diagnostics market obviously created opportunities for competitors. Critics say, however, their response has been slow and none are able to step directly into Abbott's shoes. Companies initially viewed the situation as a short-term opportunity, but now they may become more aggressive as Abbott's grip on the market weakens.
Advertisement

Related Content

Biosite: Building a Solid Franchise
A Sobered Abbott Buys i-Stat
Roche Pays $1.4 Billion for Igen and Gets Peace of Mind
Diagnostic Products Corp.: Thriving, For Now
I-Stat's $60 Million Gamble
Beckman Coulter's Play for High Growth
D-Day for Abbott
Abbott Gets Into Hot Water
Diagnostic Products Corp.'s Contrarian Bet
The Rage to Consolidate in Diagnostics

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel